Advertisement
Screener

Verastem, Inc. (VSTM) Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount

Verastem, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount

Verastem, Inc. (VSTM) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$43.99 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.

Financial Statements › Expense Statement › Income Tax

us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-04

  • Verastem, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$43.99M.
Period endEffective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month
2025-12-31-$43.99M
10-K · filed 2026-03-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
Climb Bio, Inc. (CLYM)United States$0.683B-13.03
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Faeth Therapeutics, Inc. (FTH)United States$0.750B
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
Wave Life Sciences, Inc. (WVE)$0.780B-5.56